Professional Seasonal Analysis for Trading

Apellis Pharmaceuticals, Inc. - Common Stock (APLS)

Seasonality Analysis

Stocks 9 Years Analyzed

Apellis Pharmaceuticals, Inc. - Common Stock Annual Seasonality Statistics

30.86%
Avg Annual Return
55.7%
Avg Monthly Win Rate
8/12
Positive Months
9
Years Analyzed

Apellis Pharmaceuticals, Inc. - Common Stock Monthly Seasonality Performance

Month Avg Return Win Rate Strength
January -4.31%
44%
Weak
February 1.79%
56%
Moderate
March 9.20%
56%
Moderate
April 2.54%
67%
Strong
May -2.62%
50%
Weak
June 5.13%
63%
Strong
July -5.05%
50%
Weak
August BEST 17.96%
100%
Very Strong
September WORST -15.37%
13%
Very Weak
October 3.30%
38%
Weak
November 9.15%
67%
Strong
December 9.16%
67%
Strong

Apellis Pharmaceuticals, Inc. - Common Stock 2026 vs Historical Pattern

Current Position
100
Historical Avg Position
48.18
Deviation
+51.82
Performance
Significantly Above Average

Apellis Pharmaceuticals, Inc. - Common Stock Interactive Seasonality Chart

Interactive Seasonality Chart

Unlock the full interactive seasonality chart for APLS with overlay patterns, custom date ranges, and more.

Create Free Account

Apellis Pharmaceuticals, Inc. - Common Stock Pattern Scanner

Pattern Scanner

Discover recurring patterns, anomalies, and statistically frequent setups.

Create Free Account

Apellis Pharmaceuticals, Inc. - Common Stock Seasonal Historical Performance

Historical Performance

See historical average returns for APLS across multiple timeframes.

Create Free Account

About Apellis Pharmaceuticals, Inc. - Common Stock (APLS) Seasonality

Apellis Pharmaceuticals, Inc. - Common Stock (APLS) has been analyzed using 9 years of historical data to identify seasonal patterns. Classified under Stocks, Apellis Pharmaceuticals, Inc. - Common Stock shows distinct seasonal tendencies based on historical data.

The strongest month for Apellis Pharmaceuticals, Inc. - Common Stock is historically August, with an average return of 17.96% and a win rate of 100%. Conversely, September tends to be the weakest month, averaging -15.37% return.

Looking at the full calendar year, Apellis Pharmaceuticals, Inc. - Common Stock has an average annual return of 30.86% with an overall monthly win rate of 55.7%. Out of 12 months, 8 typically show positive average returns.

The seasonal pattern for Apellis Pharmaceuticals, Inc. - Common Stock has a consistency score of 40.7 (Poor), based on 10 years of data. Higher consistency means the seasonal pattern has been more reliable across different market conditions.

Apellis Pharmaceuticals, Inc. - Common Stock Seasonality FAQ

What is the best month to buy Apellis Pharmaceuticals, Inc. - Common Stock (APLS)?

Historically, August has been the best month for Apellis Pharmaceuticals, Inc. - Common Stock, with an average return of 17.96% and a win rate of 100%. However, past performance does not guarantee future results.

What is the worst month for Apellis Pharmaceuticals, Inc. - Common Stock (APLS)?

Based on historical data, September has been the weakest month for Apellis Pharmaceuticals, Inc. - Common Stock, with an average return of -15.37%. This is a historical observation and does not guarantee future results.

How reliable is APLS seasonality data?

The seasonality analysis for Apellis Pharmaceuticals, Inc. - Common Stock is based on 9 years of historical price data. While seasonal patterns can provide useful insights, they should be combined with other forms of analysis. Past patterns do not guarantee future performance.

How can I use Apellis Pharmaceuticals, Inc. - Common Stock seasonality in my trading?

Use Apellis Pharmaceuticals, Inc. - Common Stock (APLS) seasonality as one factor in your analysis. Identify historically strong and weak months, combine with other research methods. SeasOptima provides premium tools including interactive charts, pattern scanning, and historical performance data for deeper analysis.

More Stocks Seasonality Analysis

Statistical information based on historical data. Does not constitute investment advice or recommendation. Past performance does not guarantee future results.